Halozyme Therapeutics (NASDAQ:HALO) Receives Buy Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $65.00 price objective on the biopharmaceutical company’s stock. Several other research firms have also issued reports on HALO. Morgan Stanley raised their price objective on Halozyme Therapeutics […]
More Stories
Israel: New law blocking UNRWA ‘would be a catastrophe’, Guterres warns
Two bills before the Israeli parliament could put a halt to the lifesaving operations of UN Palestine relief agency, UNRWA,...
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $35.40
LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research...
Analysts Set Spirax-Sarco Engineering plc (LON:SPX) Price Target at GBX 9,158
Spirax-Sarco Engineering plc (LON:SPX – Get Free Report) has been given an average rating of “Reduce” by the eight ratings...
Markel Group Inc. (NYSE:MKL) Receives $1,626.83 Average Target Price from Analysts
Markel Group Inc. (NYSE:MKL – Get Free Report) has been assigned an average recommendation of “Hold” from the six brokerages...
UWM Holdings Co. (NYSE:UWMC) Given Consensus Rating of “Reduce” by Analysts
UWM Holdings Co. (NYSE:UWMC – Get Free Report) has been given a consensus recommendation of “Reduce” by the seven research...
Endava plc (NYSE:DAVA) Given Average Rating of “Moderate Buy” by Brokerages
Endava plc (NYSE:DAVA – Get Free Report) has received an average rating of “Moderate Buy” from the ten ratings firms...